World-Renowned Clinical Investigator in Head & Neck Cancers Dr. Marshall Posner Joins TGH Cancer Institute as Associate Director of Clinical Investigations

His work has shaped national and international standards of care for head and neck cancers.

Tampa, FL (April 1, 2026) — Tampa General Hospital (TGH) has appointed internationally recognized medical oncologist and clinical researcher Dr. Marshall Posner as associate director of Clinical Investigations at the TGH Cancer Institute.

Posner is a world-class leader in the field of medical oncology, a gifted physician and a highly accomplished clinical researcher with over 280 peer-reviewed publications, including top-tier journals such as the New England Journal of Medicine, Nature Communications, Science, the Journal of Clinical Investigations, the Journal of Clinical Oncology, Cancer Research, the Proceedings of the National Academy of Sciences (PNAS) and the Journal of Virology, among others.

He graduated from Yale University, New Haven, Connecticut and Tufts University School of Medicine, Boston. He completed his residency in internal medicine at Boston City Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute, Boston where he earned the position of medical director of the head and neck oncology program, and associate professor at Harvard Medical School, Boston.

In 2010, Posner was recruited to the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York City as professor of Medicine, medical director, Head and Neck Cancer Program, and associate director, Cancer Clinical Trials Office. During his tenure at the Mount Sinai Health System, he also served as associate director of the Center for Personalized Cancer Therapeutics, associate director for Research Infrastructure and co-leader of the Cancer Clinical Investigation Program, National Cancer Institute Cancer Center Support Grant (P30 Grant) and co-chair, of the Protocol Review and Monitoring Committee (PRMC). He is board-certified in Internal Medicine and Medical Oncology.

Posner will continue to serve in his current role as the medical director of the Cancer Center Clinical Research Trial Office and head and neck oncologist at the Cancer Center of South Florida in Palm Beach Gardens, expanding collaboration between the two organizations. “Dr. Posner is a transformative addition to our team,” said Dr. Eduardo M. Sotomayor, vice president and executive director of the TGH Cancer Institute. “His expertise in clinical trials design and innovation, together with his ample knowledge of immunology and viral oncology, will elevate our clinical research enterprise and accelerate our ability to bring groundbreaking therapies to patients. We are also excited about his leadership within our microbial oncology program that will position Tampa General at the forefront of human-papillomaviruses (HPV)‑related cancer research.”

In his new role, Posner will collaborate closely with Tampa General and USF Health Morsani College of Medicine researchers to expand investigator‑initiated trials, pharma-sponsored and National Cancer Institute-sponsored clinical trials, strengthen translational pipelines and integrate microbial and immunologic science into new therapeutic strategies.

“Dr. Posner’s work marks a major milestone in our mission to deliver world‑class cancer care supported by groundbreaking research,” said Dr. Abraham Schwarzberg, executive vice president, chief president of Tampa General Provider Network and co‑vice president of Clinical and Translational Research, TGH | USF Health Joint Office of Clinical Research. “His leadership will help us grow a robust clinical research infrastructure and accelerate discovery for patients across the state of Florida and beyond.”

“Tampa General’s commitment to innovation, collaboration and patient‑centered care creates an ideal environment for advancing microbial oncology and developing new treatments for HPV‑related cancers,” Posner said. “I look forward to working with this exceptional team while continuing my clinical and research efforts at the Cancer Center of South Florida.”

The TGH Cancer Institute continues to grow as a statewide leader in cancer care, offering patients access to advanced therapies, multidisciplinary expertise and a rapidly expanding portfolio of clinical trials.

The TGH Cancer Institute — among Florida’s few cancer centers backed by academic medicine through its partnership with the USF Health Morsani College of Medicine — ranks among the nation’s top 10% of hospitals in U.S. News & World Report’s Best Hospitals 2025-2026. The Florida Department of Health has recognized the TGH Cancer Institute in partnership with the USF Health Morsani College of Medicine as a Cancer Center of Excellence. It holds accreditations from the American College of Surgeons Commission on Cancer, the American Society of Clinical Oncology’s Quality Oncology Practice Initiative and the Foundation for the Accreditation of Cellular Therapy for excellence in stem cell and cellular therapy. The institute is a member of the Association of American Cancer Institutes, recognized for leadership in research, treatment, education and outreach and was named among Newsweek’s America’s Best Cancer Hospitals. For more information on the TGH Cancer Institute, visit TGH Cancer Institute | Comprehensive Cancer Care in Tampa.